IIM
VRTX icon

Intact Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Intact Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-700
Closed -$326K – 345
2024
Q3 		$326K Buy
+700
New +$336K 0.01% 243
2024
Q1 		– Sell
-1,900
Closed -$773K – 274
2023
Q4 		$773K Sell
1,900
-600
-24% -$222K 0.03% 207
2023
Q3 		$869K Buy
2,500
+500
+25% +$175K 0.04% 195
2023
Q2 		$704K Sell
2,000
-400
-17% -$135K 0.03% 204
2023
Q1 		$756K Hold
2,400
– – 0.03% 192
2022
Q4 		$693K Buy
+2,400
New +$731K 0.03% 194
2022
Q3 		– Sell
-2,600
Closed -$733K – 268
2022
Q2 		$733K Sell
2,600
-200
-7% -$53.5K 0.02% 201
2022
Q1 		$731K Sell
2,800
-1,600
-36% -$380K 0.02% 215
2021
Q4 		$966K Sell
4,400
-600
-12% -$117K 0.02% 207
2021
Q3 		$907K Hold
5,000
– – 0.03% 200
2021
Q2 		$1.01M Hold
5,000
– – 0.03% 192
2021
Q1 		$1.07M Buy
+5,000
New +$1.1M 0.03% 189
2018
Q4 		– Sell
-1,190
Closed -$229K – 262
2018
Q3 		$229K Sell
1,190
-220
-16% -$39.2K 0.01% 239
2018
Q2 		$240K Buy
1,410
+20
+1% +$3.1K 0.01% 224
2018
Q1 		$227K Sell
1,390
-210
-13% -$34.3K 0.01% 218
2017
Q4 		$240K Buy
1,600
+200
+14% +$29.6K 0.01% 214
2017
Q3 		$213K Buy
+1,400
New +$211K 0.01% 241
2017
Q2 		– Sell
-5,000
Closed -$547K – 281
2017
Q1 		$547K Sell
5,000
-2,300
-32% -$202K 0.02% 157
2016
Q4 		$538K Buy
7,300
+700
+11% +$57K 0.02% 187
2016
Q3 		$576K Hold
6,600
– – 0.02% 188
2016
Q2 		$567K Hold
6,600
– – 0.02% 193
2016
Q1 		$525K Buy
6,600
+4,900
+288% +$443K 0.02% 190
2015
Q4 		$214K Buy
+1,700
New +$205K 0.01% 244

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Intact Investment Management's VRTX Position: Q4 2024 in Review

Intact Investment Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2024, closing a stake of 700 shares — an estimated $326K sold.

Intact Investment Management first reported a position in VRTX in Q4 2015 and held it in 23 quarters. The position peaked at $1.07M in Q1 2021. 1,564 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

  • Intact Investment Management reported no remaining Vertex Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Intact Investment Management sold 700 Vertex Pharmaceuticals shares in Q4 2024, an estimated $326K.
  • Intact Investment Management first reported a position in Vertex Pharmaceuticals in Q4 2015 and held it in 23 quarters.
  • Intact Investment Management's Vertex Pharmaceuticals position peaked at $1.07M in Q1 2021.
  • 1,564 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on Intact Investment Management's 13F filing for Q4 2024, filed 10 Feb 2025.